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a 3.5 to 4 fold higher risk of CAD mortality compared to 
non-diabetic women in the Framingham study. Follow up 
data for upto 24 years confi rmed the higher mortality rates 
among diabetic subjects and also a cumulative effect of age 
and diabetes.15 Co-existence of multiple risk factors among 
diabetic subjects has been shown to dramatically increase 
the mortality rates compared to non-diabetic subjects. The 
Organization to Assess Strategies for Ischemic Syndromes 
(OASIS) study showed that diabetic subjects without prior 
CAD had a similar risk for developing CAD as non-diabetic 
subjects with prior CAD.4 This was confi rmed again by the 
studies by Haffner et al5,16 who proposed that the clock for 
CAD starts ticking from the stage of IGT itself. 
PVD and diabetes: The prevalence of PVD has been shown 
to be higher among diabetic subjects compared to age and 
sex matched non-diabetic subjects.17,18 Earlier studies from 
USA, UK, Greece, and the Netherlands have clearly shown 
that diabetic subjects have a higher risk for PVD compared to 
non-diabetic subjects.19-21 Studies on Asian Indians have also 
demonstrated a similar higher prevalence of PVD among 
diabetic subjects.22 However, the overall prevalence of PVD 
in Indians was lower than that reported in western studies.22
Other risk factors for PVD in type 2 diabetic subjects are 
high triglycerides, low HDL cholesterol, hypertension and 
smoking.23
Epidemiology of diabetes and cardiovascular disease in 
Indians
Earlier studies in Western countries have confirmed 
that the prevalence of diabetes among migrant Indians is 
signifi cantly higher than in the indigenous populations.24,25
In the 1970’s diabetes among urban Indians was shown to 
be 2.1%, 26 this rose to 8.0% in 198227 and is currently 12% 
according to the recent National Urban Diabetes Study.28
Recent studies from different regions of the country have 
shown a rising prevalence of diabetes.29,30 Projections by 
WHO,31 have highlighted that India already leads the world 
in the prevalence of diabetes and would continue to hold 
the top position in the forthcoming years and numbers are 
expected to increase to 80.9 million by the year 2030.32 
The Chennai Urban Population Study (CUPS)
To determine the prevalence of diabetes and macrovascular 
disease in South Indians, we undertook a population-based 
study in urban South Indians called the Chennai Urban 
Population Study (CUPS).33 Briefl y, CUPS is a population 
based study involving two residential areas representing 
the lower and middle income group in Chennai (formerly 
Madras) in South India. All individuals aged greater than 
20 years living in these two colonies were requested to 
participate in the study. Of the total of 1399 eligible subjects 
(age ≥ 20 years), 1262 (90.2%) participated in the study. The 
study subjects underwent a glucose tolerance test (GTT) 
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Atherosclerosis
Atherosclerosis, a complicated multifactorial pathological process, affects the large and medium sized arteries 
resulting in macrovascular disease. Though the end-points of 
atherosclerosis are well defi ned, there is no clear explanation 
for the pathophysiology of atherosclerosis. However, the 
atherosclerotic process could be sequenced as functional 
changes and structural changes of the artery. The fi rst to occur 
would be functional changes in the arteries leading to the 
loss of elasticity. Structural changes like fatty degeneration 
and foam cell formation occur later leading to intimal medial 
thickening, plaque formation, finally to clogging of the 
artery interfering with blood fl ow. The plaque eventually 
ruptures with consequent intraluminal thrombosis, which 
results in the end-points like coronary artery disease [CAD], 
cerebrovascular disease [CVD] and peripheral vascular 
disease [PVD]. 1 CAD and CVD are indeed the fi rst and 
second causes of mortality worldwide.2
Macrovascular disease and diabetes
Macrovascular disease is one of the major causes of 
mortality and morbidity in diabetes, and several studies 
indicate that diabetic patients have 2-5 times higher death 
rates due to atherosclerotic disease than non-diabetic 
individuals.3-5 The prevalence of all manifestations of 
coronary artery disease like myocardial infarction, angina 
and sudden death are higher in patients with type 2 diabetes 
mellitus.6-7 In fact studies have reported CAD, to be present 
even at the time of diagnosis of diabetes and indeed even 
in prediabetic stages like impaired glucose tolerance [IGT].8 
It has been suggested that there is an eight years decrease 
in life expectancy due to diabetes.9 The protective effect 
observed among pre-menopausal women disappears after 
diabetes sets in10 and in fact diabetic women often have a 
higher risk for CAD than diabetic men.11 
CVD and diabetes: Prospective studies have shown diabetes 
to be a major risk factor for cerebrovascular disease. Mortality 
due to stroke is twice as high among subjects with diabetes. 
A follow up study on 1,160 subjects in Minnesota, (mean 
follow up years: 3.4 years) concluded that diabetes is one of 
the predictors of future cardiovascular event.12 Furthermore, 
the risk for reinfarction is shown to be higher in diabetic 
subjects compared to non-diabetic subjects.13 A recent 
study on subjects who underwent vascular surgery reported 
diabetes to be a major risk for adverse outcomes like stroke 
and hospital death.14 
CAD and diabetes: In the 1980’s Kannel et al3 was the 
fi rst to demonstrate that diabetic men and women have 
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and were categorized as having normal glucose tolerance 
(NGT), impaired glucose tolerance (IGT) or diabetes. 12 lead 
ECG was also performed and CAD was diagnosed based on 
previous medical history of CAD and / or Minnesota coding 
of ECGs.33,34
Prevalence of diabetes: Overall, 12% of the total population 
had diabetes and on age standardization this reduced to 
9.3%. Of the 152 diabetic subjects identifi ed in the CUPS 
study, 7.2% were known diabetic subjects and 4.8% were 
undiagnosed diabetic subjects. The prevalence of impaired 
glucose tolerance was 5.9% (age standardized prevalence 
5.0%). This means that 1 out of six persons in urban areas 
in India will have some degree of glucose intolerance. In 
adults aged 40 years and above, one out of four individuals 
will have glucose intolerance.35 
Prevalence of CAD: The overall crude prevalence rate of 
CAD was 11.0%, and the age-standardized fi gure was 9.0%. 
The prevalence of CAD was higher among diabetic subjects 
[21.4%] compared to 14.9% in those with IGT and 9.1% in 
subjects with normal glucose tolerance36 (Figure 1). Indeed 
the risk for CAD seemed to increase even at the stage of 
IGT and was similar to that noted among newly diagnosed 
diabetic subjects37. 
Prevalence of PVD: PVD was present in 3.2% of the 
study population. The age standardized prevalence in the 
population was 2.0%. 2.7% of the normals, 2.9% of the 
subjects with IGT and 6.3% of the diabetic subjects had PVD 
[Figure 1]. Prevalence of PVD in newly diagnosed diabetic 
subjects was 3.5% compared to 7.8% in known diabetic 
subjects.38 
Prevalence of CVD: Self reported stroke was assessed in 
the CUPS population. The overall prevalence of stroke was 
0.63% and in diabetic subjects it was 1.32% which was three 
times higher than that observed in normal subjects (0.39%) 
[Figure 1]. 
Preclinical atherosclerotic markers: Macrovascular disease is 
one of the clinical end points of atherosclerosis, which in its 
earlier stages, as discussed earlier, involves both structural 
and functional changes in the arteries. Structural changes 
can be studied using non-invasive techniques like high-
resolution ultrasound by measuring Carotid Intimal Medial 
Thickness[IMT] while functional changes can be studied 
by looking at fl ow-mediated dilatation or arterial stiffness. 
These pre-clinical atherosclerotic markers have gained wide 
recognition as they are useful surrogate markers for CAD and 
can also be used in studies on prevention and intervention 
of CAD.39,40 
In the CUPS study we examined the carotid intimal 
medial thickness (IMT) in diabetic and non-diabetic subjects. 
The mean IMT values among diabetic subjects were higher 
compared to normal subjects.40 The range of IMT values 
in non-diabetic subjects was 0.5 – 1.2 mm and in diabetic 
subjects, 0.4 – 3.0 mm. Carotid atherosclerosis (defi ned 
as IMT >1.1 mm) was present in 20% of diabetic subjects 
compared to 1% of non-diabetic subjects in CUPS [Figure 
2]. 
We also observed that the diabetic subjects had increased 
IMT at every age point compared to their non-diabetic 
counterparts.41 Further, the newly diagnosed diabetic 
subjects had signifi cantly higher IMT values compared to 
normal subjects, but signifi cantly lower compared to known 
diabetic subjects. Further analysis of the data revealed that 
diabetes per se was an important risk factor for increase in 
IMT.41 
We next looked at functional changes in arteries by 
studying endothelial dysfunction and arterial stiffness. 
Endothelial dysfunction was measured as fl ow-mediated 
dilatation (FMD) of the brachial artery using high-resolution 
B mode ultrasonography. Flow-mediated dilatation (FMD) 
was found to be reduced in diabetic patients (2.1 ± 2.95%) 
compared to age and sex matched non-diabetic subjects (6.64 
± 4.38%, p < 0.0001).42 
Arterial stiffness was measured by the Augmentation 
index of the radial artery using the Sphygmocor machine 
and was found to be signifi cantly greater in diabetic subjects 
(27.48 ± 7.41%) compared to age and sex matched non-
diabetic subjects (19.10 ± 8.19%), p < 0.0001.42
Earlier studies on intimal medial thickness on subjects 
with diabetes clearly demonstrated that atherosclerosis 
manifests 2 to 3 decades earlier among diabetic subjects 
Fig. 1: Prevalence of Macrovascular Disease - The Chennai Urban Population Study [CUPS]36,38
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compared to non-diabetic subjects.43 The Cardiovascular 
Health Study also showed higher prevalence of preclinical 
atherosclerosis compared to normals.44
Insulin and atherosclerosis 
Accelerated development of atherosclerosis in diabetes 
has been the subject of intense study in the past two decades 
which has enhanced our knowledge of both causative 
factors as well as the pathophysiology.45 These studies have 
improved our understanding of the pathogenic mechanisms 
of atherosclerosis and the trigger mechanisms that lead to 
acute clinical events in diabetes. During the last two decades 
the role of insulin in atherosclerosis has been a subject of 
heated debate. 
The association of insulin and atherosclerosis could be 
considered under two heads. The fi rst is the contribution 
of increased endogenous insulin production i.e., 
hyperinsulinemia to atherosclerosis; second the benefi cial 
effect of exogenous insulin in preventing cardiovascular 
deaths. These will be discussed in detail in the sections 
below. 
Hyperinsulinemia, insulin resistance syndrome and atheroslcerosis: 
Insulin resistance and the compensatory increase in insulin 
secretion bring about a state of chronically increased insulin 
and glucose levels in the blood (hyperinsulinemia and 
hyperglycemia), which are predecessors for both diabetes and 
cardiovascular disease. The term insulin resistance syndrome 
includes a host of abnormalities, including hypertension, 
hyperinsulinemia, hypertriglyceridemia, increased levels 
of small dense low density lipoprotein (LDL), and low high 
density lipoprotein (HDL), and hypercoagulability. These 
abnormalities constitute the Reaven’s syndrome otherwise 
named as Insulin Resistance Syndrome, or Pluri Metabolic 
Syndrome.46 
Hyperinsulinemia and atherosclerosis: There is ample 
evidence to suggest a direct role of hyperinsulinemia in 
the development of atherosclerosis through stimulation 
of vascular smooth muscle cell proliferation and arterial 
wall lipid deposition.47 Insulin has also been implicated 
as an indirect cause of atherogenesis as it promotes the 
development of hypertension and dyslipidemia.48,49 The 
Helsinki Policeman Study, which followed up 970 non-
diabetic men who were free of coronary artery disease 
revealed fasting insulin to be a predictor for CAD.50 
Insulin resistance and clustering of risk factors: Although 
insulin resistance syndrome is a cluster of various 
abnormalities , a concomitant presentation of all 
components of the syndrome is rare. Therefore, in the 
view of most experts, three components are suffi cient for 
defi ning the syndrome. The insulin resistance syndrome 
seems to explain a major part of the CAD occurrence.51 
Insulin resistance syndrome in Indians
Hyperinsulinemia,52 insulin resistance53 and other 
components of metabolic syndrome24,25,54 have been shown 
to be more prevalent among Asian Indians. The prevalence 
of Insulin resistance syndrome (IRS) defi ned using the 
European Group of Insulin Resistance (EGIR) criteria was 
found to be 11.2% among South Indians.55 The defi nition for 
IRS was as follows: - insulin resistance calculated using the 
Homeostasis Model Assessment (HOMA IR), >1.93, [being 
the 75th percentile of the total population) in combination 
with at least 2 of the following conditions; hyperglycaemia, 
hypertension, dyslipidaemia or central body obesity.34 
Factor analysis, a complex statistical technique has been 
extensively used for identifying clustering of the insulin 
resistance factors. Initially Meigs56 showed that the IRS 
components tend to cluster together. Later, using the same 
technique, Lempiainen et al57 demonstrated that this cluster 
predicts CAD in non- diabetic population followed up for 
7 years. Studies conducted on type 2 diabetic subjects51 
and the insulin resistance syndrome cluster was also 
shown to predict death.58 A similar clustering of the factors 
contributing to the insulin resistance syndrome has also 
been shown among native Indians.59 In the CUPS study 
also, we observed that the metabolic abnormalities tend 
to cluster and that subjects with more than one metabolic 
abnormality had a higher prevalence of CAD compared to 
subjects with a single metabolic abnormality.60 However, the 
role of hyperinsulinemia per se in atherogenesis is still a 
debatable issue and the association is seen mostly in middle 
aged men and not in women or in elderly men.51
Fig. 2: Prevalence Of Carotid Atherosclerosis - The Chennai Urban Population Study [CUPS]41
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Abnormalities of coagulation and fibrinolysis in insulin 
resistance: Insulin resistance is associated not only with 
the classic cardiovascular risk factors of hypertension and 
dysplipidaemia, but also with disorders of coagulation and 
fi brinolysis. Increased PAI-1 levels have been shown to 
be associated with higher insulin and proinsulin levels.61 
Patients with insulin resistance syndrome and diabetes 
mellitus tend to have increased PAI-1 levels. In our study 
on subjects with and without diabetes, PAI-1 and fi brinogen 
were higher among diabetic subjects compared to non-
diabetic subjects.62
Inflammation and insulin resistance: More recently, chronic 
subclinical infl ammation has been proposed as a part of 
the insulin resistance syndrome. Evidence from various 
studies has shown that infl ammatory markers predict the 
development of diabetes.63 In both insulin resistance and 
atherosclerosis, the acute-phase response is enhanced. 
Studies of the factors that regulate the acute-phase response 
have yielded consistent results implicating cytokines and 
growth factors in the pathophysiology of insulin resistance 
and atherosclerosis. This includes markers like C-reactive 
protein, interleukins and tumour necrosis factor.64-67 
Insulin therapy and 
atherosclerosis
Diet and exercise are the initial therapy for Type 2 
diabetic patients in whom insulin resistance is an important 
component of the altered glucose homeostasis. Both these 
forms of treatment improve the peripheral insulin sensitivity 
as well as the pancreatic beta cell function. If these measures 
do not result in the desired improvement in glycemic control, 
then oral agents or insulin are added. Both these forms of 
therapy are known to improve insulin action. 
Therapeutic role of insulin  clinical benefits: Infusion of insulin 
has been shown to have remarkable benefi t in subjects with 
myocardial infarction.68-69 The Diabetes Mellitus Insulin 
Glucose Infusion in Acute Myocardial Infarction[DIGAMI] 
Study compared long term all cause mortality in 306 
diabetic patients who received intensive treatment to 314 on 
conventional therapy.69 The mean follow up period was 3.4 
years. The study revealed a reduction in mortality by 30% in 
the group which received glucose insulin infusion initially, 
followed by four times daily insulin for three months. 
Recent studies have demonstrated that continuous insulin 
infusion reduced the mortality signifi cantly compared to 
subcutaneous insulin.70
Therapeutic role of insulin  mechanism: Apart from 
controlling hyperglycaemia insulin also intervenes with 
many other metabolic and infl ammatory pathways to prevent 
atherosclerotic endpoints. Plasma free fatty acids, which 
are increased due to enhanced catabolism, would induce 
inflammation and also worsen the clinical outcomes.71 
Normalizing free fatty acids by exogenous insulin could yield 
signifi cant benefi ts.68 Suppression of PAI-1 production by 
insulin is of benefi t as this would increase clot dissolution.68,72 
There are many other potential benefi ts of insulin, mainly 
inhibition of pro-infl ammatory early growth response gene-
1(Egr-1) and tissue factor indicating its anti-infl ammatory 
properties.68,73 The basic mechanism by which insulin acts 
as an anti-infl ammatory factor is by enhancing nitric oxide 
production.74 The vasodilatatory effect of insulin could also 
be one of the reasons for its favourable effects.75
Conclusions
It is clear from the literature that macrovascular disease 
is a common complication of diabetes, the link being 
insulin resistance and hyperinsulinemia. On the contrary 
exogenous insulin therapy in diabetic subjects has shown 
to be benefi cial. Furthermore, continuous insulin infusion is 
more advantageous than subcutaneous insulin. Appropriate 
use of insulin could help in achieving good diabetic control. 
Good control of diabetes, hypertension, hyperlipidaemia and 
obesity coupled with lifestyle changes can help to prevent 
atherosclerosis in diabetic patients. 
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